CHMP Backs Oral Siponimod (Mayzent) for Multiple Sclerosis CHMP Backs Oral Siponimod (Mayzent) for Multiple Sclerosis

The European Medicines Agency panel recommends siponimod for the treatment of adults with secondary progressive MS with active disease evidenced by relapses or imaging features of inflammatory activity.International Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news